Cencora, Inc.
As of Fiscal Year 2025 (ended September 30, 2025)
Key KPIs at a Glance
| Metric | Value |
|---|---|
| Total Revenue (FY2025) | $321.3 billion, up 9.3% year-over-year from $294.0 billion in FY2024 |
| U.S. Healthcare Solutions Segment Revenue | $290.98 billion, up 9.7% year-over-year |
| International Healthcare Solutions Segment Revenue | $30.37 billion, up 6.1% year-over-year |
| GAAP Net Income (FY2025) | $1.554 billion, up 3.0% year-over-year (net margin ~0.48%, normal for a low-margin drug distributor) |
| GAAP Diluted EPS (FY2025) | $7.96, up 5.7% year-over-year |
| Adjusted (non-GAAP) Diluted EPS (FY2025) | $16.00, up 16.3% year-over-year |
| GAAP Operating Margin (FY2025) | 0.82% of revenue, up 8 basis points year-over-year (thin margins are standard for pharma wholesale distribution) |
| Employee Count | 51,000+ worldwide team members, per company disclosure |
| U.S. Drug Distribution Market Share (Big Three combined, third-party estimate) | Commonly cited as 'over 90%' combined for McKesson, Cencora, and Cardinal Health; Drug Channels Institute's last specifically-dated figure put the Big Three at roughly 95% of U.S. prescription drug distribution in 2018, up from roughly 87% in 2013 -- no current-year precise percentage or Cencora-specific standalone share is attributed in available sourcing |
Sources: All FY2025 and FY2024 figures are company-disclosed, from Cencora, Inc.'s press release 'Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results' (filed with SEC as Exhibit 99.1 to Form 8-K, released November 5, 2025; https://www.businesswire.com/news/home/20251105392361/en/Cencora-Reports-Fiscal-2025-Fourth-Quarter-and-Fiscal-Year-End-Results and https://investor.cencora.com/news/news-details/2025/Cencora-Reports-Fiscal-2025-Fourth-Quarter-and-Fiscal-Year-End-Results/default.aspx). Segment revenue: U.S. Healthcare Solutions $290.982B, International Healthcare Solutions $30.366B (sum $321.348B rounds to the company's reported total of $321.3B). Segment operating income: U.S. Healthcare Solutions $3.575B, International Healthcare Solutions $648.3M; neither segment reported an operating loss, so operating income is shown as a pie. FY2021-FY2024 total revenue figures (used for the growth chart) are sourced from stockanalysis.com's compiled financial history (https://stockanalysis.com/stocks/cor/revenue/), cross-checked against the FY2024 figure Cencora itself cites ($293.96B) in the FY2025 release; these pre-FY2025 figures are third-party-compiled restatements of Cencora's own historical 10-K filings, not estimates. Employee count ('51,000+ worldwide team members') is company-disclosed in the same release. Net margin and operating margin are razor-thin (well under 1%), which is normal and expected for pharmaceutical wholesale distributors operating on high volume/low margin models, not a data error. The U.S. drug-distribution market-share figure is a clearly-labeled third-party estimate: Drug Channels Institute (DCI), an independent pharmaceutical-industry research firm, has published analysis (cited via Drug Channels Institute's 2019 retrospective and referenced in subsequent industry coverage, e.g. https://intuitionlabs.ai/articles/drug-wholesaler-market-concentration and https://www.drugchannels.net/2024/10/five-crucial-trends-facing-us-drug.html) that the 'Big Three' wholesalers -- McKesson, Cencora (formerly AmerisourceBergen), and Cardinal Health -- together controlled roughly 87% of U.S. prescription drug distribution in 2013, rising to roughly 95% by 2018, and are commonly described industry-wide as controlling 'over 90%' of the market today; DCI's more recent '2024-25 Economic Report on Pharmaceutical Wholesalers' projects combined Big Three drug-distribution revenue of about $776 billion for calendar 2024 but a current precise combined percentage was not available in the portions of that report accessible during this research. No individual per-company market-share percentage (e.g., Cencora's own standalone share) is specifically attributed anywhere found, so none is presented here.